Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 11/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | PPARG | P37231 | 11/20 | 0.59 |
| ▸ | FABP2 | P12104 | 1/20 | 0.54 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10706463 | 0.84 | PPARA (0.61) | PPARAMEN1KMT2ACYP2C19CYP1A2 | |
| SCHEMBL17967827 | 0.82 | ALDH1A1 (0.50) | PPARAMEN1KMT2ACYP2C19CYP1A2 | |
| SCHEMBL12885848 | 0.82 | PPARA (0.60) | PPARAMEN1KMT2ACYP2C19CYP1A2 | |
| SCHEMBL6780983 | 0.81 | ALDH1A1 (0.44) | PPARAMEN1KMT2ACYP2C19CYP1A2 | |
| SCHEMBL11545612 | 0.80 | PPARA (0.71) | PPARAMEN1KMT2ACYP2C19CYP1A2 | |
| SCHEMBL2174559 | 0.80 | PPARA (0.51) | PPARAMEN1KMT2ACYP2C19CYP1A2 | |
| SCHEMBL11786162 | 0.80 | PPARA (0.57) | PPARAMEN1KMT2ACYP2C19CYP1A2 | |
| SCHEMBL11786169 | 0.80 | PPARA (0.57) | PPARAMEN1KMT2ACYP2C19CYP1A2 | |
| SCHEMBL2558556 | 0.80 | ADORA3 (0.56) | PPARAMEN1KMT2ACYP2C19CYP1A2 | |
| SCHEMBL1045831 | 0.79 | PPARA (0.69) | PPARAMEN1KMT2ACYP2C19CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129101-A1 | Compound, Pharmaceutical Composition Comprising the Same and Method for Treating Cancer Using the Same | NATIONAL TSING HUA UNIVERSITY (TW) | 2025-04-24 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| EP-3253754-B1 | 2-PHENYL-3H-IMIDAZO[4,5-B]PYRIDINE DERIVATES USEFUL AS INHIBITORS OF MAMMALIAN TYROSINE KINASE ROR1 ACTIVITY | KANCERA AB (SE) | 2021-03-31 | — | — | EP | disclosed |
| US-10550113-B2 | 2-phenyl-3H-imidazo[4,5-B]pyridine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity | KANCERA AB (SE) | 2020-02-04 | — | — | US | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| EP-2558577-B1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION AS (DK) | 2018-12-12 | — | — | EP | disclosed |
| CN-107567445-A | It can be used as 2 phenyl 3H imidazos [4,5 B] pyridine derivates of mammal EGFR-TK ROR1 activities inhibitor | 坎塞拉有限公司 | 2018-01-09 | — | — | CN | disclosed |
| US-20180002329-A1 | 2-PHENYL-3H-IMIDAZO[4,5-B]PYRIDINE DERIVATES USEFUL AS INHIBITORS OF MAMMALIAN TYROSINE KINASE ROR1 ACTIVITY | KANCERA AB (SE) | 2018-01-04 | — | — | US | disclosed |
| WO-2016124553-A1 | 2-PHENYL-3H-IMIDAZO[4,5-B]PYRIDINE DERIVATES USEFUL AS INHIBITORS OF MAMMALIAN TYROSINE KINASE ROR1 ACTIVITY | KANCERA AB (SE) | 2016-08-11 | — | — | WO | disclosed |
| EP-1409489-A1 | 6-PHENYLDIHYDROPYRROLOPYRIMIDINEDIONE DERIVATIVES | Almirall Prodesfarma, S.A. (ES) | 2004-04-21 | — | — | EP | disclosed |
| US-20030187041-A1 | Propionic acid derivatives | URBAHNS KLAUS (DE) | 2003-10-02 | — | — | US | disclosed |
| EP-1328508-A2 | PROPIONIC ACID DERIVATIVES WITH PPAR-ALPHA ACTIVATING PROPERTIES | Bayer Aktiengesellschaft (DE) | 2003-07-23 | — | — | EP | disclosed |
| US-6548538-B2 | Potent peroxisome proliferator activated receptor (PPAR)-alpha-activating compounds; propionic acid 2-subsituted with an N-(phenylaminocarbonylalkyl), N-(2-furanylmethyl)aminoalkylphenyl group | BAYER AKTIENGESELLSCHAFT (DE) | 2003-04-15 | — | — | US | disclosed |
| US-20030032671-A1 | Propionic acid derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2003-02-13 | — | — | US | disclosed |
| WO-2003000694-A1 | 6-PHENYLDIHYDROPYRROLOPYRIMIDINEDIONE DERIVATIVES | ALMIRALL PRODESFARMA S.A. (ES) | 2003-01-03 | — | — | WO | disclosed |
| WO-2002028821-A2 | PROPIONIC ACID DERIVATIVES WITH PPAR-ALPHA ACTIVATING PROPERTIES | BAYER AKTIENGESELLSCHAFT (DE) | 2002-04-11 | — | — | WO | disclosed |
| US-4163859-A | ANTILIPEMIC, FUNGICIDES, BACTERICIDES | G. D. SEARLE & CO. (US) | 1979-08-07 | — | — | US | disclosed |
| US-3994955-A | Substituted phenoxydialkylacetic acids and esters | G. D. SEARLE & CO. (US) | 1976-11-30 | — | — | US | disclosed |
| US-3903132-A | 2-(2-Cyano-2-arylethenylphenoxy)-2,2-dimethyl acetic acids and esters | SEARLE & CO | 1975-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187041-A1 | Propionic acid derivatives | PPARA, PPARD, PPARG | PPARA 1/4885MEN1 4797/4885KMT2A 3323/4885 |
| US-20030032671-A1 | Propionic acid derivatives | PPARD, PPARA, PPARG | PPARA 2/4885MEN1 4851/4885KMT2A 4215/4885 |
| US-10550113-B2 | 2-phenyl-3H-imidazo[4,5-B]pyridine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity | ROR1, RORB, RORA | PPARA 2229/4885MEN1 2648/4885KMT2A 1278/4885 |
| US-20250129101-A1 | Compound, Pharmaceutical Composition Comprising the Same and Method for Treating Cancer Using the Same | RB1, TP53, ASH2L | PPARA 1553/4885MEN1 62/4885KMT2A 1114/4885 |
| US-20180002329-A1 | 2-PHENYL-3H-IMIDAZO[4,5-B]PYRIDINE DERIVATES USEFUL AS INHIBITORS OF MAMMALIAN TYROSINE KINASE ROR1 ACTIVITY | ROR1, RORB, RORA | PPARA 2229/4885MEN1 2648/4885KMT2A 1278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.